Business Wire

Alibaba’s Luohan Academy Celebrates First Anniversary

Share

Luohan Academy, an open-research initiative by Alibaba Group, celebrated its first anniversary in Hangzhou this week, gathering Nobel Laureates, renowned economists, social scientists, tech pioneers and professors from leading universities to tackle the disruptions and other issues we face from rapid digitization of the global economy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190627005994/en/

Dr. Chen Long, Director of the Luohan Academy, spoke at the Luohan Academy Digital Economy Conference (Photo: Business Wire)

Dr. Chen Long, Director of the Luohan Academy, spoke at the Luohan Academy Digital Economy Conference (Photo: Business Wire)

The Academy was established last year to address the economic consequences and social disruptions caused by a tech-driven economy. Complementing Alibaba’s DAMO Academy, a global research program for cutting-edge technologies, Luohan Academy examines the implications that digital technologies will have on societies in the future.

Over two full days of presentations and panel discussions, participants aired their views on how to deal with the widening digital gap in the global economy and challenges in the job market caused by digital technologies. Other topics included whether a platform economy can be beneficial to all participants, whether we need new governance and regulations tailored for the digital age, what the new ethics underlying emerging technologies are and how to ensure the changes we’re seeing make the global economy more inclusive.

Dr. Chen Long, Director of the Luohan Academy, commented: “It was exciting to have over 200 renowned academics, including Nobel Laureates and economists, gather together, discussing and sharing their valuable insights on how to address universal challenges arising from the rapid development of digital technologies.”

“By drawing on the wisdom of global academics who come from different backgrounds and cultures, we hope the Luohan Academy can promote thought-provoking discussions on controversial, yet critical, issues facing society. These discussions could serve as a guidepost for social scientists, economists, educators, policy makers and private sector leaders to examine what roles they can play to bolster inclusive growth. As such, we hope to shed light on the path toward a more dynamic, balanced and fair digital economy.”

In Chinese’s Buddhist teachings, “Luohans” are enlightened and empathetic beings who are willing to take actions to alleviate world from suffering. Below are some issues discussed during the conference, with the intent to inspire more dialogues to maximize the benefits of technologies in the digital age:

  • Should we first embrace digital technology or first address and attempt to control potential risks? It took 46 years for electricity to reach 50 million users, 14 years for computers, seven years for the Internet and 19 days for Pokemon Go. Decision-making time is getting shorter, and the cost of missing out by failing to make a decision or by making the wrong one has never been larger.
  • Will technology widen the gap among people around the world or provide a level playing field? The technological revolution we’re undergoing has increased the number of people the earth can support from one billion to more than seven billion. But it has also triggered two world wars. Today, the key is to narrow the disparity in wealth, so we ask ourselves how we can benefit as many people as possible at the fastest speed.
  • How will automation affect employment for humans? Will the ongoing tech revolution lead to new jobs and shorter working hours? What is the future of work?
  • How will technology affect money transfers and payments across borders? Will digital financial services lead to more risks, even as they become more popular? What uncertainties will we face from purely digital money?
  • What are the ethics of artificial intelligence? When you have an autonomous driving system using AI, and the driverless car has to make a split-second decision, should an algorithm make the unconscionable choice between hitting an old man on the left side of the road, or a child on the right, if impact cannot be avoided?
  • Who owns data in the digital world and who should benefit from it? The records of car drivers aren’t particularly meaningful to most individuals. But, if shared, they make navigation software more accurate. Sole ownership doesn’t create as much benefit as pooling that data, provided privacy is protected.

For more information, please visit the website of the Luohan Academy: https://www.luohanacademy.com/about/start

About Luohan Academy

Luohan Academy was founded in Hangzhou on June 26th, 2018. It is an open research institute initiated by Alibaba Group and launched by world-renowned social scientists, which consist of the academy’s academic committee, including six Nobel Price laureates in economics. Luohan Academy will dedicate itself to collaborating with world-class social scientists and practitioners to collectively explore and shape the consensus regarding how to embrace the social and economic transformations brought by digital technology. The purpose of Luohan Academy is to serve the society at large, addressing the most important global challenges as well as having an eye for the humanity’s long-term future.
https://www.luohanacademy.com/about/start

Contact information

Crystal Liu
Alibaba Group
+852 6378 5626
crystal.liu@alibaba-inc.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bempedoic Acid Significantly Reduces LDL-Cholesterol on Top of Statin Therapy: Results of the CLEAR Wisdom Trial, Published in the Journal of the American Medical Association12.11.2019 16:08:00 CETPress release

Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced the publication of results from the Phase 3 CLEAR Wisdom trial in the Journal of the American Medical Association (JAMA).1 Bempedoic acid is currently undergoing review for marketing authorisation by the European Medicines Agency (EMA) and by the United States Food and Drug Administration (FDA). CLEAR Wisdom, a Phase 3, double-blind, randomised trial, evaluated the efficacy, long-term safety and tolerability of bempedoic acid 180 mg versus placebo in 779 patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolaemia (HeFH) inadequately controlled with current lipid-modifying therapies, added on to maximally-tolerated statin therapy, which may mean no statin at all.1 The JAMA publication includes results for the primary efficacy endpoint of low-density lipoprotein cholesterol (LDL-C) lowering at 12 weeks and key secondary endpoints of safety and tolerability over 52

 Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicines12.11.2019 15:57:00 CETPress release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirms that the Regional Pharmaceutical Procurement Service in Northern Ireland has accepted an offer for access to all currently licensed Vertex cystic fibrosis (CF) medicines and any future indications of these medicines under the same terms as the recently announced agreement with NHS England. This means that once the contract is finalized, patients with CF in Northern Ireland ages 2 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene will have access to ORKAMBI ® (lumacaftor/ivacaftor) and CF patients ages 12 years and older who either have two copies of the F508del mutation or one copy of the F508del mutation and a copy of one of the other 14 licensed mutations will have access to SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor. We will support the arrangements being put in place to ensure clinicians will be able to prescribe to el

Andersen Global Announces First Collaboration in Croatia12.11.2019 14:30:00 CETPress release

Andersen Global announced today that it signed a Collaboration Agreement with one of Croatia’s largest law firms, KALLAY & PARTNERS Ltd. The addition of the Zagreb-based firm establishes Andersen Global’s presence in the country and continues the expansion of the organization in the region. Founded in 2006, KALLAY & PARTNERS Ltd. is led by Founder and Office Managing Director Marko Kallay. Under his leadership, the firm provides both foreign and domestic clients with a broad range of legal services, including banking and finance, commercial and corporate law, dispute settlement, arbitration and mediation, labor law, and regulator relationships. “Our firm values commitment, transparency, reliability and providing clients with the best-in-class legal services, and these values align well with Andersen Global’s standards and vision,” said Marko. “This collaboration will allow us to take our client service to the next level and expand our footprint more broadly. We are excited to work clos

Report: The Delivery Economy Uncovering Misalignment In the Supply Chain12.11.2019 14:00:00 CETPress release

The rapid growth of the Delivery Economy — the pervasive sentiment in which customers expect low-cost, fast and highly transparent delivery of goods — is pressuring companies to quickly address structural supply chain challenges that make it difficult for them to meet increasing customer demands, according to a new report from project44, the global leader in advanced visibility for shippers and logistics service providers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191112005320/en/ (Graphic: Business Wire) The new report from project44, “Aligning the Supply Chain In The Age Of The Delivery Economy,” is based on a blind survey of 300 supply chain professionals. It is the second in a series of reports examining the emergence and impact of the Delivery Economy. The report highlights key issues plaguing both B2B and B2C supply chains and preventing adoption of the organization-wide delivery strategies that will be critical t

Modern Governance 8.0: New Report from Stanford’s Rock Center and Diligent Institute Reveals Corporate Directors Are Less Shareholder-Centric and Success Is No Longer Defined Solely by Shareholder Returns12.11.2019 14:00:00 CETPress release

In a new report released today, Diligent Institute and the Rock Center for Corporate Governance at Stanford University found that board directors consider both shareholder and stakeholder needs when making strategic decisions – reinforcing a stakeholder movement that embraces modern governance. The report, “Stakeholders Take Center Stage: Director Views on Priorities and Society,” includes responses and interviews with nearly 200 directors of public and private corporations globally. According to the survey, a vast majority of corporate directors (89%) believe it is important or very important for their company to consider the interests of non-shareholder stakeholders – such as employees, local communities, and the general public – as they work to achieve business objectives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191112005426/en/ The findings of this report echo the sentiments of the recent Business Roundtable “Stat

Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilised12.11.2019 13:36:00 CETPress release

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth Phase III study in the empagliflozin heart failure programme. The study will assess whether in-hospital administration of empagliflozin 10 mg daily improves heart failure outcomes when initiated in people hospitalised for any type of acute heart failure event once they have been stabilised. The study will include participants both with and without type 2 diabetes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191112005650/en/ Heart failure is the leading cause of hospitalisation in Europe and the US, and half of people with heart failure are expected to die within five years of diagnosis.2,3 However, outcomes for patients after they have been hospitalised for heart failure are poor, with a 15 percent mortality and 30 percent readmission rate within 60 to 90 days of discharge from hospital.4 Initiating treatment in